WM Announces Cash Dividend

HOUSTON--(BUSINESS WIRE)-- WM (NYSE: WM) today announced the declaration of a quarterly cash dividend of $0.825 per share payable Mar. 28, 2025, to stockholders of record on Mar. 14, 2025.

ABOUT WM

WM (WM.com) is North America's leading provider of comprehensive environmental solutions. Previously known as Waste Management and based in Houston, Texas, WM is driven by commitments to put people first and achieve success with integrity. The company, through its subsidiaries, provides collection, recycling and disposal services to millions of residential, commercial, industrial, medical and municipal customers throughout the U.S. and Canada. With innovative infrastructure and capabilities in recycling, organics and renewable energy, WM provides environmental solutions to and collaborates with its customers in helping them pursue their sustainability goals. WM has the largest disposal network and collection fleet in North America, is the largest recycler of post-consumer materials and is a leader in beneficial use of landfill gas, with a growing network of renewable natural gas plants and the most landfill gas-to-electricity plants in North America. WM's fleet includes more than 12,000 natural gas trucks – the largest heavy-duty natural gas truck fleet in the industry in North America. WM Healthcare Solutions provides collection and disposal services of regulated medical waste, as well as secure information destruction services, in the U.S., Canada and Western Europe. To learn more about WM and the company's sustainability progress and solutions, visit Sustainability.WM.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217311600/en/

WM

Website
investors.wm.com

Analysts
Ed Egl
713.265.1656
[email protected]

Media
Toni Werner
[email protected]

Source: WM

You May Also Be Interested In

• SkyDrive Marks a Total of 300 Flights without Incident
• RGREEN INVEST Partners with Arverne Founder and CEO Pierre Brossollet Through GEOGREEN to Advance Geothermal Energy and Strengthen Europe's Energy Security
• PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)